Enezate Tariq, Alkhatib Deya, Raja Joel, Chinta Viswanatha, Patel Mitul, Omran Jad
Division of Cardiovascular Diseases, University of Tennessee Health Science Center, Memphis, TN, USA.
Division of Cardiovascular Diseases, Memphis Veterans Affairs Medical Center, Memphis, TN, USA.
Curr Cardiol Rep. 2022 Apr;24(4):377-382. doi: 10.1007/s11886-022-01658-9. Epub 2022 Feb 7.
Management of intracardiac masses, such as right heart thrombi and catheter-related vegetations, can be challenging. Many patients are high-risk candidates for surgical extraction due to multiple comorbidities and risk of distal embolization. In this review, we highlight the advancements in percutaneous approaches for treatment of intracardiac masses utilizing AngioVac (AngioDynamic, Latham, NY).
With the Food and Drug Administration (FDA) approval of the AngioVac System in 2009, a growing body of evidence has proven it to be a feasible and effective tool to extract thrombi and masses from the iliocaval system and the right heart. In this review, we highlight the feasibility of AngioVac System (AngioDynamic, Latham, NY) based on the published cases series and registries. Future randomized controlled trials are needed to establish an algorithmic approach in treating intracardiac masses.
心内肿物的管理，如右心血栓和导管相关赘生物，可能具有挑战性。由于多种合并症和远端栓塞风险，许多患者是手术摘除的高危候选者。在本综述中，我们重点介绍了利用AngioVac（AngioDynamic，纽约州拉瑟姆）经皮治疗心内肿物方法的进展。
随着美国食品药品监督管理局（FDA）在2009年批准AngioVac系统，越来越多的证据证明它是从髂股静脉系统和右心提取血栓和肿物的一种可行且有效的工具。在本综述中，我们根据已发表的病例系列和登记资料重点介绍AngioVac系统（AngioDynamic，纽约州拉瑟姆）的可行性。未来需要进行随机对照试验，以建立治疗心内肿物的算法方法。
